Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
1999-08-09
2003-10-21
Housel, James (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S114000, C424S234100, C424S239100, C435S030000, C435S034000, C435S342000
Reexamination Certificate
active
06635260
ABSTRACT:
This invention relates to methods and compositions useful to prevent and treat
Clostridium difficile
-associated diseases.
Clostridium difficile
-associated diseases (CDAD) are the most frequently identified causes of nosocomial diarrhea (that is, in healthcare facilities), producing both endemic and epidemic diarrhea. CDAD incidence ranges from <1% to 7.8% of hospital discharges. CDAD prolongs hospitalization, increases the costs of care, and causes considerable morbidity, especially in the 10-20% who relapse, and a mortality of 0.6-2.3%. Elderly patients and those who have long hospital stays are at particularly high risk.
Horizontal transmission of
C. difficile
in the hospital to susceptible patients receiving antibiotics accounts for the vast majority of CDAD incidence. No infection control method has been widely successful at preventing transmission, and prophylactic measures aimed at preventing symptoms if transmission occurs have proven cumbersome, ineffective, or both. Therefore, new and innovative approaches to prevent CDAD are needed.
In animals,
C. difficile
-related diseases cause great economic losses. Notably, in horse breeding, young foals are extremely susceptible, infection generally resulting in death; chinchillas are also vulnerable. Antibiotic treatment in animals is not only expensive, but is not completely effective.
There is a need for relatively inexpensive and effective prophylactic methods and treatments.
Although use of a non-toxigenic strain of
C. difficile
has been suggested as a solution, selection of strains has been random, and results ambiguous or discouraging. For example, Wilson and Sheagren (1983) report that colonization of cefotoxin-treated hamsters with a strain of
C. difficile
, said to be non-toxigenic, but not further characterized, before challenge with toxigenic
C. difficile
resulted in only 72% improvement in survival compared to controls. Even more discouraging, when toxigenic and non-toxigenic strains were given at the same time, no significant survival benefit was obtained.
Borriello and Barclay (1985) reported that prior colonization of clindamycin-treated hamsters with non-toxigenic strains of
C. difficile
protected them for at least a short time period from subsequent colonization with a toxigenic strain. The non-toxigenic strains were given designations, but were not further characterized. In total, 13 of 18 “protected” hamsters survived for up to 27 days, whereas all 27 animals challenged with the toxigenic strain alone died within 48 hours. However, even in toe “protected” animals, the toxigenic strain eventually became dominant and caused disease, and death occurred in most cases due to infection. The authors concluded that the extent to which this sort of approach may be therapeutically useful was difficult to assess.
Seal et al. (1987) reported that two patients (designated A and B) with relapsing
C. difficile
diarrhea following metronidazole and vancomycin therapy were colonized with a non-toxigenic avirulent
C. difficile
strain given orally in three doses. Patient A did not suffer a further relapse during the four months that she was studied after treatment with non-toxigenic
C. difficile
. Patient B did suffer a relapse, but it was reported as milder than previous relapses. The authors acknowledged that there was no showing that the bacteriotherapy actually prevented or mitigated relapse. Indeed, in one of the two patients, it had not prevented relapse. Obviously, conclusions on only two patients are questionable. The authors also stated that there was a need for further studies before this approach should be considered for trials in the hospital.
Corthier and Muller (1988) reported that administering a non-toxigenic strain of
C. difficile
to gnotobiotic mice from 18 hours to 10 days before challenge with toxigenic
C. difficile
resulted in 100% survival, however, the controls exhibited 60% survival in this experiment, suggesting only about 40% improvement. It cannot be determined from the article how long this level of protection persisted. The mice appear to have been observed for only eight days after administration of the toxigenic
C. difficile.
Borriello (1988) reviewed bacteriotherapy approaches for the prevention and treatment of
C. difficile
infection of the gut, including use of whole fecal mixtures, synthetic mixtures of fecal organisms, lactobacilli, the yeast
Saccharomyces boulardii
, and non-toxigenic
C. difficile
in vitro, and in vivo in animals and in vivo in humans. He concluded that all of the bacteriotherapy approaches need to be further evaluated, but that a non-toxigenic strain of
C. difficile
may fulfill criteria for a “cleaner” and well defined preparation.
No reports of attempts to use
C. ditficile
bacteriotherapy to protect against CDAD are known since 1988. Experimental bacteriotherapy is in clinical use in the U.S. with
Saccharomyces boulardii
, a yeast, which is reported to show some benefit in reducing relapses and in preventing antibiotic-associated diarrhea, but is not effective against
C. difficile
diarrhea (McFarland et al., 1994; Surawicz et al., 1989). A problem with Saccharomyces is that twice daily administration is required for four weeks, making compliance difficult for patients.
The successful use of rectal instillation of feces and bacterial mixtures of fecal organisms to treat chronic relapsing
C. difficile
has been reported in six patients (Tvede and Rask-Madsen, 1989). Use of bacteriotherapy has not been wide-spread due to reluctance by physicians and patients aesthetically to use fecal preparations. At present, methods and compositions for specific prevention of
C. difficile
diarrhea have not been reported.
SUMMARY OF THE INVENTION
The present invention provides methods and compositions for preventing and treating CDAD (
C. difficile
-associated disease) in subjects including humans and non-human animals, e.g. mammals and birds. “Subjects” are persons or animals who have received antimicrobials o antineoplastics (which also have antimicrobial activity). For prevention of
C. difficile
disease, a composition of a selected non-toxigenic strain of
C. difficile
is administered within about 24 hrs. after antibiotic (antimicrobial) or antineoplastic agents. This is to allow time for suppression of the normal intestinal flora, but not enough time for toxigenic strains of
C. difficile
to become established in the gastrointestinal tract. Examples of types of antimicrobial agents known to cause risk of
C. difficile
disease in human and non-human animals or birds include cephalosporins, clindamycin, ampicillin, tetracyclines.
For treatment of subjects who have
C. difficile
disease, first antibiotics (usually vancomycin or metronidazole) must be administered that are directed to control of the disease, then—to prevent a relapse, the compositions of the present invention are administered.
The methods of the present invention comprise administering to the subject an effective amount of spores (generally in the order of 5×10
5
to 10
6
colony-forming units) of a selected non-toxigenic strain of
C. difficile
. Higher or repeated doses may be required for treatment than for prevention. “Effectiveness” is determined by clinical criteria showing the risk of developing CDAD is reduced by 80% or more compared to comparably exposed patients or animals in the same environment.
An aspect of the invention is compositions for use in the method, said compositions including selected non-toxigenic strains of
C. difficile
. Certain non-toxigenic strains (types) of
C. difficile
are found to prevent disease better against specific toxigenic types of
C. difficile
than against other toxigenic types. Methods to select these strains are an aspect of the present invention.
A suitable non-toxigenic strain is a strain selected from the M, T, C, AP or other non-toxigenic groups as described by Clabots et al. (1993) or as genetically engineered to be non-toxigenic. These groups are selected because their relative high frequencies as isolates from person
Foley Shanon
Housel James
LandOfFree
Methods and compositions for prevention and treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for prevention and treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for prevention and treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3132491